

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC)  
and the Drug Safety and Risk Management Advisory Committee (DSaRM)***

FDA White Oak Campus, Building 31 Conference Center, the Great Room (Rm. 1503)  
10903 New Hampshire Avenue, Silver Spring, Maryland  
November 14, 2018

**AGENDA**

---

*The committees will discuss new drug application (NDA) 209774, for an immediate-release oral tablet formulation of oxycodone, which is intended to resist common methods of physical or chemical manipulation and to deter intravenous and intranasal abuse, submitted by SpecGx LLC, for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The committees will also be asked to determine whether the Applicant adequately demonstrated that the abuse-deterrent properties of the proposed product are sufficient to include this information in the product label, and whether the product should be approved.*

---

8:00 a.m.	Call to Order and Introduction of Committee	<b>Brian Bateman, MD</b> Acting Chairperson, AADPAC
8:05 a.m.	Conflict of Interest Statement	<b>Moon Hee V. Choi, PharmD</b> Designated Federal Officer, AADPAC
8:10 a.m.	FDA Opening Remarks	<b>Sharon Hertz, MD</b> Director, Division of Anesthesia, Analgesia, and Addiction Products (DAAAP) Office of Drug Evaluation II (ODE-II) Office of New Drugs (OND), CDER, FDA
8:30 a.m.	<b>APPLICANT PRESENTATIONS</b>	<b>SpecGx LLC</b>
	Introductions	<b>Martha Sclicher, PhD</b> Vice President, R&D Mallinckrodt Pharmaceuticals
	Public Health Need for Abuse-Deterrent IR Opioid Analgesics	<b>Richard Dart, MD, PhD</b> Director Rocky Mountain Poison & Drug Center Professor of Emergency Medicine University of Colorado School of Medicine Executive Director, RADARS <sup>®</sup> System
	Category 1 <i>In Vitro</i> Studies	<b>Edward Cone, PhD</b> Principal Scientist Drug Delivery and Abuse Deterrent Drug Products Pinney Associates

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

*Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC)  
and the Drug Safety and Risk Management Advisory Committee (DSaRM)*  
November 14, 2018

**AGENDA (cont.)**

---

**APPLICANT PRESENTATIONS (CONT.)**

Nonclinical Excipient Safety Studies     **Mike Orr, PhD, DABT**  
President/CEO  
Orr Nonclinical Consulting, LLC

Intranasal Human Abuse Potential  
Study     **Sandra Comer, PhD**  
Professor of Neurobiology (in Psychiatry)  
Division on Substance Use Disorders  
Columbia University

Clinical Perspective     **Jeff Gudin, MD**  
Director  
Pain Management and Palliative Care  
Englewood Hospital and Medical Center

9:45 a.m.     Clarifying Questions

10:00 a.m.     **BREAK**

10:15 a.m.     **FDA PRESENTATIONS**

MNK-812 Introduction and Overview     **Jennifer L. Nadel, MD**  
Medical Officer  
DAAAP, ODE-II, OND, CDER, FDA

In Vitro Category I Abuse-Deterrent  
Studies of MNK-812     **Valerie Amspacher, PharmD**  
Chemistry, Manufacturing and Controls Reviewer  
Division of New Drug Products II  
Office of New Drug Products (ONDP)  
Office of Pharmaceutical Quality, CDER, FDA

Nonclinical Safety Assessment of  
MNK-812 Excipients     **R. Daniel Mellon, PhD**  
Pharmacology Toxicology Supervisor  
DAAAP, ODE-II, OND, CDER, FDA

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC)  
and the Drug Safety and Risk Management Advisory Committee (DSaRM)***

November 14, 2018

**AGENDA (cont.)**

---

**FDA PRESENTATIONS (CONT.)**

Examination of Intranasal Human  
Abuse Potential Study  
MNK48121013

**James M. Tolliver, PhD**  
Pharmacologist  
Controlled Substance Staff  
Office of the Center Director  
CDER, FDA

Review of Recent Epidemiologic  
Data on Use, Misuse and Abuse of  
Oxycodone

**Tamra Meyer, PhD, MPH**  
Team Lead, Prescription Drug Abuse Team  
Division of Epidemiology II  
Office of Pharmacovigilance and Epidemiology  
Office of Surveillance and Epidemiology  
CDER, FDA

MNK-812 Clinical Summary of  
Abuse Deterrence

**Jennifer L. Nadel, MD**

11:30 a.m. Clarifying Questions

11:45 a.m. **LUNCH**

12:45 p.m. **OPEN PUBLIC HEARING**

1:45 p.m. Charge to the Committee

**Sharon Hertz, MD**

1:50 p.m. Questions to the Committee/  
Committee Discussion

3:00 p.m. **BREAK**

3:15 p.m. Questions to the Committee/  
Committee Discussion (cont.)

5:00 p.m. **ADJOURNMENT**